Goodwin

Kingsley L. Taft

Deals
4
Latest
Jun 2026
Most deals in
Biotech

Firm

  • Goodwin Law firm · 2026 · 4 deals
Deals by year
Kingsley L. Taft: deals by year0123420252026 YTD: 3 M&A2026 YTD: 1 Equity raisings42026 YTDM&AEquity raisings

Often works with

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deals Kingsley L. Taft was named on, most recent first
Jun 2026 Parabilis Medicines ––PlacementLegal adviser to the issuerCompleted75.0Biotech+1Parabilis Medicines placement
Apr 2026 Tubulis EQT Life Sciences (LSP 7 fund)Gilead SciencesAcquisitionLegal adviser to Tubulis (target)Announced3,150.0Biotech+2Gilead Sciences acquisition of Tubulis
Mar 2026 Ouro Medicines –GileadAcquisitionLegal adviser to Ouro Medicines (target)Announced1,675.0Biotech+1Gilead acquisition of Ouro Medicines
Mar 2026 Pikavation SynnovationNovartisAcquisitionLegal adviser to Synnovation Therapeutics (seller)Announced2,000.0Biotech+2Novartis acquisition of Pikavation

Deals where Kingsley L. Taft is named on the firm's deal team, by the firm or the press.

Suggest a correction

A missing deal, a wrong firm, a move between firms, or two different people shown as one. A link to a public source helps.